Form 4: Supernus Executive Gains Shares from Performance Units

Supernus Pharmaceuticals' Sr. VP of IP and CSO, Padmanabh P. Bhatt, acquired 1,250 common shares through performance unit settlement, with 581 shares withheld for taxes.

Summary

• Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (SUPN), reported changes in beneficial ownership.
• On August 25, 2025, Mr. Bhatt acquired 1,250 shares of common stock upon the settlement of Performance Share Units (PSUs) granted on February 23, 2023.
• The PSUs vested due to the achievement of individual performance objectives established on June 12, 2023.
• Concurrently, 581 shares of common stock were disposed of by the company to satisfy tax withholding requirements related to the PSU vesting, at a price of $41.46 per share.
• Following these transactions, Mr. Bhatt's direct beneficial ownership of Supernus common stock stands at 13,718 shares.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates an executive achieved performance objectives, leading to the vesting of equity awards. This suggests successful individual performance within the company. However, it's a routine compensation event, not a major operational or financial announcement.

Positives

• The reporting person received 1,250 shares of common stock from the settlement of Performance Share Units, indicating the achievement of individual performance objectives.
• The vesting of PSUs suggests successful performance by a key executive, which can be a positive signal for the company's operational execution.

Negatives

• 581 shares were withheld by the company to cover tax obligations, which is a standard practice but reduces the net shares received by the executive.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It primarily reports past transactions related to executive compensation.

Management Comments

• Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.
• Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
• On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

Industry Context

This Form 4 filing is a routine disclosure of an insider's stock transactions, specifically related to executive compensation through performance-based equity awards. Such filings are common across all industries, including pharmaceuticals, and reflect standard practices for incentivizing and retaining key personnel. It does not provide direct insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• The use of Performance Share Units (PSUs) as a component of executive compensation is a common practice across the pharmaceutical industry and other sectors, aligning executive incentives with company performance and shareholder value. Companies like Pfizer, Merck, and Johnson & Johnson frequently utilize similar equity-based compensation structures.
• The withholding of shares for tax purposes upon vesting is a standard and legally compliant method for managing tax obligations associated with equity awards, consistent with practices observed at most publicly traded companies.

Stakeholder Impact

• **Shareholders:** The vesting of PSUs for an executive aligns management's interests with shareholder value creation, as the awards are performance-based. The tax withholding is a standard administrative process.
• **Employees:** This filing highlights the company's executive compensation structure, which may influence perceptions of fairness and opportunity within the broader employee base, particularly regarding performance-based incentives.

Next Steps

• Future vesting events for any remaining or newly granted equity awards to the reporting person would be reported in subsequent Form 4 filings.

Key Dates

Keywords

Supernus Pharmaceuticals, SUPN, Performance Share Units, PSU vesting, insider transaction, executive compensation, stock ownership, pharmaceuticals